Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction

J Am Soc Nephrol. 2020 Jul;31(7):1509-1521. doi: 10.1681/ASN.2019070728. Epub 2020 Jun 11.

Abstract

Background: Uremic toxicity may play a role in the elevated risk of developing cognitive impairment found among patients with CKD. Some uremic toxins, like indoxyl sulfate, are agonists of the transcription factor aryl hydrocarbon receptor (AhR), which is widely expressed in the central nervous system and which we previously identified as the receptor of indoxyl sulfate in endothelial cells.

Methods: To characterize involvement of uremic toxins in cerebral and neurobehavioral abnormalities in three rat models of CKD, we induced CKD in rats by an adenine-rich diet or by 5/6 nephrectomy; we also used AhR-/- knockout mice overloaded with indoxyl sulfate in drinking water. We assessed neurologic deficits by neurobehavioral tests and blood-brain barrier disruption by SPECT/CT imaging after injection of 99mTc-DTPA, an imaging marker of blood-brain barrier permeability.

Results: In CKD rats, we found cognitive impairment in the novel object recognition test, the object location task, and social memory tests and an increase of blood-brain barrier permeability associated with renal dysfunction. We found a significant correlation between 99mTc-DTPA content in brain and both the discrimination index in the novel object recognition test and indoxyl sulfate concentrations in serum. When we added indoxyl sulfate to the drinking water of rats fed an adenine-rich diet, we found an increase in indoxyl sulfate concentrations in serum associated with a stronger impairment in cognition and a higher permeability of the blood-brain barrier. In addition, non-CKD AhR-/- knockout mice were protected against indoxyl sulfate-induced blood-brain barrier disruption and cognitive impairment.

Conclusions: AhR activation by indoxyl sulfate, a uremic toxin, leads to blood-brain barrier disruption associated with cognitive impairment in animal models of CKD.

Keywords: chronic kidney disease; dementia; uremia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine
  • Animals
  • Blood-Brain Barrier / diagnostic imaging
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / metabolism*
  • Carbon / pharmacology
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / metabolism*
  • Disease Models, Animal
  • Indican / blood
  • Indican / cerebrospinal fluid
  • Indican / pharmacology*
  • Male
  • Mice, Knockout
  • Nephrectomy
  • Neuropsychological Tests
  • Oxides / pharmacology
  • Permeability
  • Radiopharmaceuticals / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Aryl Hydrocarbon / genetics
  • Receptors, Aryl Hydrocarbon / metabolism*
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / physiopathology*
  • Single Photon Emission Computed Tomography Computed Tomography
  • Technetium Tc 99m Pentetate / metabolism
  • Uremia / blood*
  • Uremia / complications

Substances

  • Oxides
  • Radiopharmaceuticals
  • Receptors, Aryl Hydrocarbon
  • Carbon
  • AST 120
  • Adenine
  • Indican
  • Technetium Tc 99m Pentetate